Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

257.78

-1.58 (0.61%)

as of Oct 21, 2026, 8:00:00 pm Market Closed.

697 watching

PAST TOP PICK

(Top Pick Jul 3/09, Up 14.83%) Would still buy.

TOP PICK

Indicative of why investors need to invest outside of Canada. Has a multi-decade record of dividend increases. Regulatory issues are behind it. Low double-digit earnings growth over the next couple of months. Well run. Business: 2/5ths from pharma 2/5ths medical devices and 1/5th consumer health care.

PAST TOP PICK

(A Top Pick Jan 29/09. Up 10.8%.) Not just pharmaceuticals, but a consumer's product company as well. Still likes. Great balance sheet and pays nice dividends.

TOP PICK

Cheap at 14X price to earnings. Gone through a little struggle in the last couple of years because of generic competition but that is basically at an end now and has a pipeline of new drugs that will not be subject to this. Well diversified. Over 3% dividend yield.

PAST TOP PICK

(A Top Pick Dec 22/08. Up 12.92%.)

BUY

Great holding. Gives you a piece of pharma, consumer goods and medical devices. 3.2% dividend. Trades at a reasonable multiple.

DON'T BUY

Great leadership name. Trading at around 12X forward earnings. Healthcare stocks tend not to do well when the market starts moving up. Quarterly estimates are being revised downwards. 3.25% dividend. Would prefer Pfizer (PFE-N).

PAST TOP PICK

(A Top Pick Oct 23/08. No change.) Still likes. Not just a pharmaceutical company but also consumer and medical devices businesses. Great balance sheet. 3%+ dividend. Historically has done a great job of growing its equity 10%-15%. Great core holding.

WAIT

(Market Call Minute.) Probably not a Buy for the next 3 or 4 months but longer-term it would be a buy.

PAST TOP PICK

(A Top Pick Sept 3/08. Down 15%.) Made a V base. 200-day moving average around $55. Would love to buy if it broke into new highs. Anything above $62-$63 would be confirmation of the beginning of a new leg.

BUY

Household brand company with a tremendous franchise. Solid balance sheet and solid dividend. No matter what happens, it is not going to hurt you too badly. Be aware that on dividends outside Canada, you pay a lot more tax.

BUY ON WEAKNESS

Probably one of the best US pharmaceuticals. Also have consumer products. Steady earnings and dividend growth for over 20 years. The only risk is the currency effect by investing in a US company. Would like it at $57-$58.

TOP PICK

Healthcare space so is reasonably defensive. Well diversified including consumer products, prescription drugs and medical devices. Fantastic balance sheet management. About a 4% yield. History of increasing dividends.

PAST TOP PICK

(A Top Pick July 3/09. Up 7.31%.) Likes the diverse products in their pharmaceutical and medical devices as well as their consumer products area. Still a Buy.

TOP PICK

Sector most out of favour right now is healthcare. This is one of the most respected companies in the world with a very strong balance sheet. A leader in all its businesses. Wonderful consumer business. Very cheap with a 14 multiple.

Showing 466 to 480 of 630 entries

Most Recent Experts

Gordon Reid

GoodReid Investment Counsel

Keith Richards

ValueTrend Wealth Management

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Bruce Campbell (2)

Stone Castle Investment Management Inc.

Jim Cramer - Mad Money

CNBC

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)